What's Happening?
Cellares has announced strategic partnerships with five technology providers—Tecan, Advanced Instruments, Cytek Biosciences, Slingshot Biosciences, and AltemisLab—to advance its Cell Q platform. This platform is designed to automate quality control testing for cell therapy manufacturing, matching the commercial-scale throughput of the Cell Shuttle. The partnerships aim to enhance capabilities in high-throughput sample preparation, liquid-handling verification, flow cytometry, and synthetic controls. The Cell Q system can support automated QC release testing for up to 6,000 cell therapy batches annually, offering scalability and efficiency compared to traditional manual methods. The first performance data from Cell Q will be presented at the 10th CAR-TCR Summit.
Why It's Important?
The development of the Cell Q platform represents a significant advancement in the field of cell therapy manufacturing. By automating quality control processes, Cellares addresses the growing demand for scalable and efficient production methods in the biotech industry. This innovation reduces labor dependency and batch failure risks, potentially lowering manufacturing costs and accelerating the availability of life-saving therapies. The partnerships with technology providers ensure that the platform meets stringent regulatory requirements, supporting compliance and audit-readiness. This could benefit both early-stage and commercial developers by facilitating tech transfer and global scale-up.
What's Next?
Cellares plans to present the automated QC testing capabilities of Cell Q at the upcoming CAR-TCR Summit. This presentation will highlight how the platform integrates high-throughput sample preparation and real-time data reporting, reducing operational burdens. The company is also expanding its network of IDMO Smart Factories globally, with facilities under construction in Europe and Japan. These developments aim to enhance the production capacity and quality of cell therapies, meeting global patient demand.
